On July 30, REMEGEN fell 5.02% in regular trading, trading at HK$78.5/share, with turnover of HK$131 million. The decline came after news emerged that the company's key ophthalmic pipeline candidate faced a regulatory setback.

According to publicly available information, on July 28 the National Medical Products Administration (NMPA) published drug notification delivery records involving seven drugs, including REMEGEN's RC28-E (Ilifu Pu Alpha Intraocular Injection, acceptance number CXSS2500103). In standard regulatory practice, receipt of such a notification typically indicates that the drug registration application was either not approved or voluntarily withdrawn by the applicant. RC28-E is one of the company's core pipeline assets targeting ophthalmic diseases.

Within the Biotechnology sector, the overall tone was broadly negative. Among peers, INNOVENT BIO fell 3.51%, AKESO fell 2.77%, BEIGENE fell 2.61%, 3SBIO fell 2.46%, and SKB BIO fell 5.1%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)